PTC Therapeutics Issues Inducement Stock Grants to New Hires
PTC Therapeutics approved stock options and RSUs for new employees under a Nasdaq rule permitting inducement grants outside standard shareholder plans.
PTC Therapeutics, Inc. announced that on Sept. 22, 2026, its board approved inducement equity awards for newly hired employees, the Warren, N.J.-based biopharmaceutical company disclosed in a regulatory notice dated Sept. 25, 2026.
The grants consist of non-statutory stock options to purchase an aggregate of 51,270 shares of PTC common stock, along with 37,995 restricted stock units. The awards were issued pursuant to Nasdaq Listing Rule 5635(c)(4), which allows companies to grant equity compensation to new employees as a material inducement to joining the firm without first obtaining shareholder approval.
Read more Crescent Real Estate Sells Luxury Hotel at Avalon in Alpharetta →
Inducement grants are a common tool used by publicly traded companies to attract specialized talent, particularly in competitive sectors such as biotechnology, where equity compensation is a significant part of total compensation packages. By structuring awards under the Nasdaq inducement exemption, companies can move quickly to close on key hires without the delay of a shareholder vote.
PTC Therapeutics trades on the Nasdaq Global Select Market under the ticker symbol PTCT. The company is focused on the development and commercialization of treatments for rare diseases. No financial terms beyond the share and unit counts were disclosed in the announcement.
Continue reading at All Financial Services & Investing.
